Macular Degeneration: Drugs
(asked on 19th November 2015) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government what assessment they have made of the effectiveness of bevacizumab in the treatment of age-related macular degeneration.
This question was answered on 1st December 2015
No assessment by the Government has been made on the effectiveness of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD) as there are two other effective, licensed treatments for wet AMD which have been recommended by the National Institute for Health and Care Excellence. Bevacizumab is not licensed for use in the treatment of wet AMD.